Dr. Plimack on Frontline Pembrolizumab for Urothelial Carcinoma
Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the KEYNOTE-052 trial investigating pembrolizumab (Keytruda) in the frontline setting for patients with urothelial carcinoma.
Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the KEYNOTE-052 trial investigating pembrolizumab (Keytruda) in the frontline setting for patients with urothelial carcinoma.
The KEYNOTE-052 investigated pembrolizumab in the frontline setting, explains Plimack. Additionally, the PD-L1 biomarker and gene signature that predicted full response had been investigated in this trial.
The search for better biomarkers to help select treatment is still requires further investigation states Plimack.
